DISP-10

N/A

Report date: 2026/04/24 20:01:59

First In Class

Base Information

Drug NameDISP-10

Drug Alias NameDISP-10

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-cell maturation protein modulatorsT lymphocyte replacements

TargetsB-cell maturation protein

Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursStomach Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDispatch Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesDispatch Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsEsophageal adenocarcinomaSolid tumoursStomach Neoplasms +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A